ADVANCED BREAST CANCER
Clinical trials for ADVANCED BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new ADVANCED BREAST CANCER trials appear
Sign up with your email to follow new studies for ADVANCED BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New pill combo shows promise for tough breast cancer
Disease control Not yet recruitingThis study tests a new tablet (QLC1401) combined with standard targeted therapies for people with a common type of advanced breast cancer (ER+/HER2-). About 96 participants will join to find the safest dose and see if the combination shrinks tumors. The goal is to better control …
Matched conditions: ADVANCED BREAST CANCER
Phase: PHASE1, PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New drug delivery methods tested for tough breast cancer
Disease control Not yet recruitingThis study is for people with HER2-positive advanced breast cancer. It tests a drug called SHR-A1811 given in different ways (like injection or infusion) to see which works best and is safest. About 60 adults who have had up to 2 prior treatments will take part. The goal is to sh…
Matched conditions: ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated May 17, 2026 00:59 UTC
-
New drug combo targets advanced breast cancer in phase 2 trial
Disease control Not yet recruitingThis study tests two experimental drugs, AK146D1 and AK112, given together to people with advanced HER2-negative breast cancer. The goal is to see if the combination is safe and can shrink tumors or slow the disease. About 200 adults aged 18 to 75 will take part.
Matched conditions: ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated May 17, 2026 00:52 UTC
-
Could a device help control advanced breast cancer?
Disease control Not yet recruitingThis study tests a device called TheraBionic P1 in 82 people with advanced or metastatic HR-positive, HER2-negative breast cancer who have already tried standard hormone therapies. The goal is to see if the device can slow cancer growth and improve survival. Participants will use…
Matched conditions: ADVANCED BREAST CANCER
Phase: NA • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New combo aims to control advanced breast cancer
Disease control Not yet recruitingThis study tests two experimental drugs, camizestrant and atirmociclib, taken together by people with a certain type of advanced breast cancer (ER-positive, HER2-negative) that has worsened after previous treatment. The main goal is to check the safety of the combination and see …
Matched conditions: ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated May 11, 2026 20:39 UTC
-
New study: can a single shot help fight advanced breast cancer by shutting down ovaries?
Disease control Not yet recruitingThis early-stage trial is testing a single injection of ZOLADEX 10.8 mg to temporarily stop the ovaries from producing hormones in premenopausal women with a certain type of advanced breast cancer (HR+/HER2-). The goal is to see if the drug can effectively suppress ovarian functi…
Matched conditions: ADVANCED BREAST CANCER
Phase: PHASE1 • Sponsor: TerSera Therapeutics LLC • Aim: Disease control
Last updated May 11, 2026 20:37 UTC
-
Tailored diet may ease side effects for advanced cancer patients
Symptom relief Not yet recruitingThis study looks at whether a personalized diet plan can help women with advanced gynecologic or breast cancer feel better during treatment with antibody-drug conjugates (ADCs). About 100 women will be randomly assigned to either a customized diet or general Mediterranean diet ad…
Matched conditions: ADVANCED BREAST CANCER
Phase: PHASE2 • Sponsor: TNC Nutrición Terapéutica S.L. • Aim: Symptom relief
Last updated May 05, 2026 11:54 UTC